Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Substrate-labeled fluorescent immunoassay for phenobarbital

L M Krausz, J B Hitz, R T Buckler

    Therapeutic Drug Monitoring
    |January 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Simultaneous determination of total IgE and allergen-specific IgE in serum by the MAST chemiluminescent assay system.

    Clinical chemistry·1985
    Same author

    Application of the MAST Immunodiagnostic System to the determination of allergen-specific IgE.

    Clinical chemistry·1984
    Same author

    Production and characterization of monoclonal antibody to gentamicin.

    Hybridoma·1984
    Same author

    Analytical methods for therapeutic drug monitoring.

    The American journal of medical technology·1983
    Same author

    Simultaneous determination of phenytoin and phenobarbital in serum or plasma by substrate-labeled fluorescent immunoassay.

    Clinical chemistry·1983
    Same author

    Colorimetric immunoassays using flavin adenine dinucleotide as label.

    Methods in enzymology·1983

    A new assay accurately measures anticonvulsant phenobarbital (PB) levels in serum. This substrate-labeled fluorescent immunoassay offers a sensitive and specific method for therapeutic drug monitoring.

    Area of Science:

    • Biochemistry
    • Analytical Chemistry
    • Pharmacology

    Background:

    • Therapeutic drug monitoring of anticonvulsants like phenobarbital (PB) is crucial for patient management.
    • Existing assays may have limitations in sensitivity, specificity, or ease of use.

    Purpose of the Study:

    • To develop and validate a novel substrate-labeled fluorescent immunoassay for quantifying serum phenobarbital (PB).

    Main Methods:

    • A competitive binding assay utilizing a fluorescently labeled PB derivative (GUPB) and bacterial beta-galactosidase.
    • GUPB is nonfluorescent until hydrolyzed; antibody binding prevents hydrolysis, enabling competitive quantification.
    • Assay involves mixing serum, antibody, enzyme, and GUPB, followed by fluorescence measurement.

    Related Experiment Videos

    Main Results:

    • The assay demonstrates high specificity and sensitivity for phenobarbital detection.
    • Fluorescence intensity is directly proportional to serum PB concentration.
    • Correlation with a commercial enzyme immunoassay was high (r=0.97) with interassay precision <7%.

    Conclusions:

    • The developed assay is a specific, sensitive, and user-friendly method for phenobarbital measurement.
    • It shows excellent correlation with existing methods, making it suitable for clinical application.
    • This assay facilitates accurate therapeutic drug monitoring of phenobarbital.